Alr Technologies Sg Ltd. · OTC:ALRTF
Alr Technologies Sg — Investor Presentation (August 2022)
16 slides from Alr Technologies Sg's investor presentation, August 2022
Slide 1: Smarter Diabetes Management Investor Presentation
Stock Ticker: ALRT Smarter Diabetes Investor Presentation Management August 2022
Slide 2: Forward Looking Statement
Forward Looking Statement Legal disclosure CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This presentation includes certain “forward-looking statements” as defined under applicable securities legislation. All information and statements contained herein that are not clearly historical i
Slide 3: Meet ALRT
Meet ALRT Transforming diabetes care Milestones Mission To assist patients and healthcare professionals Completed In Progress in improving diabetes outcomes and quality of care, while reducing complications and Pilot & Clinical Trials in the US, GluCurve Pet CGM manufacturing containing costs. Canad
Slide 4: Diabetes Monitoring Systems: BGM vs CGM
Diabetes Monitoring Systems BGM vs CGM Blood Glucose Meter (BGM) ▪ Blood is placed on test strip and inserted into a glucose meter to display glucose levels ▪ Humans use a lancet to draw blood from finger, pets typically require a syringe and must be done by a veterinarian ▪ Few data points with no
Slide 5: ALRT Divisions: 1. Animal Health
ALRT Divisions Animal & Human 1. Animal Health Investor Presentation, Aug ‘22 OTCMKTS : ALRT Confidential | © 2022 ALR TECHNOLOGIES INC. | ALL RIGHTS RESERVED 5
Slide 6: The GluCurve Pet CGM
The GluCurve Pet CGM Revolutionizing diabetes management ▪ Hardware ▪ Up to 14-day sensor life ▪ Glucose readings every 3 minutes ▪ 1 year shelf life ▪ Bluetooth communicates between CGM and mobile app ▪ Software ▪ iOS and Android mobile app for pet owners ▪ Web based platform for veterinarians ▪ Gl
Slide 7: Animal Health Opportunity
Animal Health Opportunity Anticipated to become the new standard of care The current way of monitoring Our solution for monitoring glucose levels in pets glucose levels in pets In-clinic Blood Glucose Curve The GluCurve™ Pet CGM ▪ Labor Intensive ▪ Effortless ▪ Blood is drawn from vein of pet via sy
Slide 8: Market Research
Market Research Conducted by SmartPharma, April 2021 Highlights How Often Doctors of Veterinary Medicine (DVMs) See Pets for Diabetes Mellitus (DM) ▪ 97% of veterinarians surveyed said they would use The GluCurve Pet CGM 2% ▪ 2+ GluCurve Pet CGM’s are needed initially for newly Once a year diagnosed
Slide 9: Market Size
Market Size Diabetic animal population Estimated US pet population (2021) Estimated EU pet population (2020) ▪ Dogs 89.7 million x 0.34% diabetic rate = 304,980 ▪ Dogs 90 million x 0.34% diabetic rate = 306,000 ▪ Cats 95.6 million x 0.58% diabetic rate = 554,480 ▪ Cats 110 million x 0.58% diabetic r
Slide 10: ALRT Divisions: 2. Human Health
ALRT Divisions Animal & Human 2. Human Health Investor Presentation, Aug ‘22 OTCMKTS : ALRT Confidential | © 2022 ALR TECHNOLOGIES INC. | ALL RIGHTS RESERVED 10
Slide 11: The Diabetes Challenge
The Diabetes Challenge Current methods The problem with current diabetes management can be summarized in two words: Clinical Inertia The failure to advance therapy on a timely basis ▪ A Cleveland Clinic study across 7,389 patients showed the following patients received no intensification over a year
Slide 12: The ALRT Approach
The ALRT Approach Our unique diabetes management solution ALRT addresses clinical inertia by: ▪ Shifting diabetes care from patient self-management to active patient management by the healthcare provider ▪ Providing artificial intelligence (AI) assisted management of large patient populations ▪ Pate
Slide 13: Our Process
Our Process The ALRT Diabetes Management Solution Mass data collection Our powerful AI, Findings are delivered via through low-cost BGM Predictive A1C®, combs our patient management or CGM through millions of data portal directly to the points to suggest healthcare provider treatment plans Investor
Slide 14: The Future for ALRT Human Health
The Future for ALRT Human Health Low-cost human CGMs Continuous Glucose Monitor (CGM) use rate ▪ According to the CDC, over 37 million Americans have diabetes, and approximately 90-95% of them have type 2 diabetes ▪ However, according to a 2021 market analysis by Seagrove Partners, only 2.4 million
Slide 15: Objectives Timeline
Objectives Timeline 2022 and 2023 ▪ GluCurve Global Sales and ▪ GluCurve Commercialization - ▪ Conventions & Conferences ▪ Release 2nd Generation Distribution Agreement (Aug) Soft Launch (Oct) (Jan) GluCurve Model DX (Jun) ▪ GluCurve Pre-Launch ▪ Implement Suggestive Insulin ▪ Pursue NYSE American l
Slide 16: Thank you!
Thank you! Have any questions? For more information or investment opportunities please contact ir@alrt.com Stock Ticker: ALRT Investor Presentation August 2022
ALR Technologies SG — Investor Presentation (August 2022) on 6ix